To improve the efficacy of anti-programmed death-ligand 1 (anti-PD-L1) therapy in advanced gastric cancer, it is necessary to identify precise predictive biomarkers or models for the optimized selection of patients with gastric cancer who might benefit the most from immunotherapy1. The gene discussed is CD274; the disease is gastric cancer.